digital health companies weight loss glp-1 Novo Nordisk seeks partners to boost GLP-1RA outcomes GLP-1 Shortage = Over -
Description
More than 2% of Kentuckians use the drugs which mimic a hormone that triggers the release of insulin.
GLP-1 Patent Expiry: The Next Big Pharma Race Has Already Begun GLP-1 agonists like semaglutide, tirzepatide, and liraglutide have completely reshaped the global diabetes and obesity landscape
What is Microdosing
This category includes compounds such as semaglutide, tirzepatide, and retatrutide, each handled under structured sourcing and verification protocols
With semaglutide patent expiry expected next year, competitive entry could pull prices down from current ~1726k/month and accelerate adoption
The products were being sold via the company's website
